{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:05:15Z","timestamp":1764079515727,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.revmed.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T18:17:44Z","timestamp":1571941064000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Toxicit\u00e9s immunologiques induites par les inhibiteurs de checkpoint en 2019\u00a0: mise au point"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-9238","authenticated-orcid":false,"given":"T.","family":"Comont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-8584","authenticated-orcid":false,"given":"J.","family":"Belliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Alric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Acket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Michot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Beyne-Rauzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2019.09.005_bib0350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jamiaopen\/ooy045","article-title":"Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis","volume":"2","author":"Wang","year":"2019","journal-title":"JAMIA Open"},{"key":"10.1016\/j.revmed.2019.09.005_bib0360","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4\u00a0and PD-1\/PD-L1\u00a0inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.revmed.2019.09.005_bib0365","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.rmr.2017.08.006","article-title":"Toxicit\u00e9 des inhibiteurs de points de contr\u00f4le immunitaires","volume":"35","author":"Delaunay","year":"2018","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.revmed.2019.09.005_bib0370","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0375","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0380","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0385","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0390","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0395","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.revmed.2017.01.004","article-title":"Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge","volume":"38","author":"Kostine","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2019.09.005_bib0400","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0405","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0410","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0415","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2\u00a0trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4\u00a0and anti-PD-1\u00a0antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0425","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14737159.2018.1440209","article-title":"Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead","volume":"18","author":"Patil","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.revmed.2019.09.005_bib0430","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.revmed.2019.09.005_bib0435","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0440","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2019.09.005_bib0445","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0450","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0455","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-018-0443-6","article-title":"Immune checkpoint inhibitor-related acral vasculitis","volume":"6","author":"Comont","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0460","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2019.09.005_bib0465","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0470","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: Anti-CTLA-4\u00a0and Anti-PD-1\u00a0blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.revmed.2019.09.005_bib0475","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0480","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0485","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0490","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.revmed.2019.09.005_bib0495","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bulcan.2019.02.003","article-title":"Endocrinopathies induites par l\u2019immunoth\u00e9rapie: synth\u00e8se du consensus 2018\u00a0de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie","volume":"106","author":"Castinetti","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0500","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105\u00a0patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0505","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.09.005_bib0510","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0515","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1\u00a0cancer immunotherapy","volume":"77","author":"Le Burel","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.09.005_bib0520","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2018-213677","article-title":"Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1","volume":"78","author":"Michot","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.09.005_bib0525","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.revmed.2017.11.008","article-title":"Sarcoidosis post-anti-PD-1\u00a0therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission","volume":"39","author":"Yatim","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2019.09.005_bib0530","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0535","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2019.09.005_bib0540","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0545","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0550","first-page":"50","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2019.09.005_bib0555","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Granulomatose sarco\u00efdosique survenant sous inhibiteurs de point de contr\u00f4le immunitaire","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.revmed.2019.09.005_bib0560","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0565","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.revmed.2019.09.005_bib0570","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: A narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0575","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br F J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0585","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0590","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0595","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0600","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0605","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.revmed.2019.09.005_bib0610","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","article-title":"Cardiac complications in immune checkpoint inhibition therapy","volume":"6","author":"Tajiri","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.revmed.2019.09.005_bib0620","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2019.09.005_bib0625","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/annonc\/mdx701","article-title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","volume":"29","author":"Michot","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0630","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1\u00a0or anti-PD-L1\u00a0immunotherapy: A descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0635","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1\u00a0Anticancer Immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0640","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1\u00a0therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0645","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death-1\u00a0pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1\u00a0antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0655","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0660","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.cllc.2019.04.007","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced nsclc and remote history of thymoma","volume":"20","author":"Lara","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0665","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11864-019-0661-2","article-title":"Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies","volume":"20","author":"Lippner","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0670","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.03.006","article-title":"Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis","volume":"113","author":"Tedbirt","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2019.09.005_bib0675","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.revmed.2019.09.005_bib0680","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1\u00a0in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4\u00a0and anti-PD1\u00a0in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0685","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2019.09.005_bib0345","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:07Z","timestamp":1759336927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319306563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0248866319306563"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.09.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s immunologiques induites par les inhibiteurs de checkpoint en 2019\u00a0: mise au point","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}